Supplemental Figure 6 from Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

Systemic treatment of PD-L1 IgG reduces the amount of human T-cells in mice at 24 hrs post-injection.</p

Supplemental Figure 4 from Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

Co-infection of Onc.Ad with HDPD-L1 increased PD-L1 mini-body in vitro, but PD-L1 mini-body was undetectable in the serum of mice.</p

Supplemental Materials and Methods from Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

Supplemental Materials and Methods</p

Supplemental Figure 5 from Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

PD-L1 mini-body is expressed at tumor site 10 days post-injection of HER2.CAR T-cells, but minimally impacts CD4+ T-cell phenotype long-term.</p

Supplemental Table 1 from Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

LD50 of Onc.Ad, HDAd or CAd-VEC in each cell line.</p

Supplemental Figure Legends from Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

Supplemental Figure Legends</p

Supplemental Figure 2 from Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

PD-L1 mini-body induces dose-dependent IFNb secretion and T-cell proliferation similar to anti-PD-L1 IgG in MLR.</p

Supplemental Figure 3 from Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

Anti-PD-L1 antibody and PD-L1 mini-body enhance HER2.CAR T-cell proliferation in vitro.</p

Supplemental Figure 1 from Armed Oncolytic Adenovirus–Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

Cancer cells express HER2 and PD-L1 expression is induced in the presence of recombinant IFN�, and HER2.CAR T-cells express PD-1 in the presence of target cells.</p

Additional file 1: of CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation

Figure S1. Generation of 2nd generation CAR.MUC1 T cells. (A) Schematic of 2nd generation CAR.MUC1 (2G) retroviral construct. (B) Co-expression of 4/7ICR and 2G CAR as detected by mOrange and anti-IgG, respectively. Summary data (right panel) shows percentage of double-positive cells (mean ± SEM, n = 4). (PPTX 298 kb